Triptorelin regulatory status
Current status of Triptorelin in the United States: FDA approved. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Triptorelin?
Regulatory: FDA approvedWADA: WADA prohibitedVerified: Verified Sep 23, 2026
- FDA and compounding
- FDA approved as Trelstar (triptorelin pamoate) in June 2000 for palliative treatment of advanced prostate cancer, with 3 month and 6 month depots added later, and as Triptodur in June 2017 for central precocious puberty in children 2 years and older. Triptorelin is approved in Europe for endometriosis, fibroids, breast cancer, and assisted reproduction, uses that are off label in the US. Compounding is not permitted beyond patient specific needs because approved products exist.
- WADA
- WADA prohibited
- Access path
- Prescription from a urologist, oncologist, or pediatric endocrinologist, administered in clinic as a depot injection.
- Fertility clinics prescribe triptorelin off label (often imported or compounded acetate) as an IVF trigger.
- Not available through telehealth peptide clinics.
Full Triptorelin page: evidence, dosing in the literature, and sources
How has the status of Triptorelin changed over time?
No dated regulatory event has been recorded for Triptorelin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Triptorelin and the source of each dated event.
- [1]FDA prescribing information for Trelstar (triptorelin pamoate for injectable suspension), via DailyMedFDA, 2026
- [2]WADA Prohibited List, section S2 (GnRH and its analogs in males)WADA, 2026
- [3]FDA prescribing information for Triptodur (triptorelin) for extended-release injectable suspension, via DailyMedFDA, 2025